1. Home
  2. CAC vs OMER Comparison

CAC vs OMER Comparison

Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$57.18

Market Cap

923.2M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$19.39

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
OMER
Founded
1875
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
923.2M
844.6M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
CAC
OMER
Price
$57.18
$19.39
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$47.00
$32.50
AVG Volume (30 Days)
71.1K
2.3M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
98.15
EPS
2.64
0.77
Revenue
$41,739,000.00
$29,868,000.00
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
$233.22
P/E Ratio
$21.70
$24.83
Revenue Growth
16.96
N/A
52 Week Low
$35.00
$3.94
52 Week High
$60.59
$19.65

Technical Indicators

Market Signals
Indicator
CAC
OMER
Relative Strength Index (RSI) 50.87 73.82
Support Level $56.91 $18.00
Resistance Level $60.07 $19.65
Average True Range (ATR) 2.18 0.81
MACD -0.05 -0.19
Stochastic Oscillator 62.41 85.47

Price Performance

Historical Comparison
CAC
OMER

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: